4 terminated. 4 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
| Phase 3 | 1 | Terminated 1 |
Follow Granulomatosis with Polyangiitis: new trials by email Literature Review of Granulomatosis with Polyangiitis trials Research Report on Granulomatosis with Polyangiitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PR3-AAV Resilient Remission or PRRR Obinutuzumab, Rituximab - Granulomatosis With Polyangiitis, Microscopic Polyangiitis | Phase 2 | Terminated | Mayo Clinic | 6 | 2023-06-30 | 2026-05-06 |
| Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA IFX-1 low dose, IFX-1 high dose, Placebo - Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | Phase 2 | Terminated | InflaRx GmbH | 20 | 2018-10-15 | 2022-05-26 |
| Abatacept in ANCA Associated Vasculitis Abatacept (Orencia) - ANCA-associated Vasculitis | Phase 2 | Terminated | Imperial College London | 7 | 2007-11-01 | 2015-05-29 |
| Plasma Exchange for Renal Vasculitis Plasma exchange, Intravenous methyl prednisolone, Methyl prednisolone - Wegener's Granulomatosis, Microscopic Polyangiitis | Phase 2 / Phase 3 | Terminated | Cambridge University Hospitals NHS Foundation Trust | 150 | 1995-03-01 | 2011-08-03 |
Microscopic Polyangiitis (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2) · Churg-Strauss Syndrome (1) · Vasculitis (1)
Autoimmune Diseases (4) · Brain Diseases (4) · Cardiovascular Diseases (4) · Central Nervous System Diseases (4) · Cerebral Small Vessel Diseases (4) · Cerebrovascular Disorders (4) · Immune System Diseases (4) · Lung Diseases (4) · Lung Diseases, Interstitial (4) · Nervous System Diseases (4) · Respiratory Tract Diseases (4) · Skin Diseases (4) · Skin Diseases, Vascular (4) · Skin and Connective Tissue Diseases (4) · Systemic Vasculitis (4)
Abatacept (1) · Plasma Exchange (1) · Rituximab (1) · obinutuzumab (1) · vilobelimab (1)
Cambridge University Hospitals NHS Foundation Trust (1) · Imperial College London (1) · InflaRx GmbH (1) · Mayo Clinic (1)
United Kingdom (2) · United States (2) · Canada (1)
Alan Salama (1) · Korinna Pilz, MD, MS (1) · Niels Rasmussen, MD (1) · Peter A. Merkel, MD, MPH (1) · Ulrich Specks, MD (1)